高级检索
当前位置: 首页 > 详情页

Plasma Siglec-5 and CD163 as Novel Biomarkers for Fulminant Myocarditis

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE ◇ 预警期刊

单位: [1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hubei Key Lab Genet & Mol Mech Cardiol Disorders, Wuhan 430074, Peoples R China [2]Huazhong Univ Sci & Technol, Div Cardiol, Wuhan 430074, Peoples R China
出处:
ISSN:

关键词: Siglec-5 CD163 biomarker fulminant myocarditis

摘要:
Fulminant myocarditis (FM) is the severest type of myocarditis and requires timely diagnosis and treatment. However, effective biomarkers for early diagnosis of FM are limited. First, 12 common inflammatory cytokines levels in the plasma of patients with FM were measured using human cytokine 12-Plex assay. Then, enzyme-linked immunosorbent assay (ELISA) was used to detect the plasma levels of another eight cytokines that we previously reported on. Moreover, a Spearman correlation test was employed to investigate the correlations between the plasma cytokine levels and the clinical parameters of patients with FM. Finally, receiver operating characteristic (ROC) curve analyses were performed to assess the diagnostic performance of plasma cytokine levels for the detection of FM. Five of the twelve common inflammation cytokines were significantly altered in patients with FM, but none of them was correlated with the severity of FM. Six of the eight significantly changed cytokines that we previously reported on were validated by ELISA. Among these, sST2, Siglec-5, and CD163 were negatively correlated with ejection fraction values. Furthermore, plasma Siglec-5 and CD163 levels were found to be associated with the severity of FM. Finally, both plasma Siglec-5 and CD163 showed outstanding diagnostic performance for FM. The current study identified plasma Siglec-5 and CD163 as valuable novel biomarkers for the early diagnosis of FM.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 3 区 工程技术
小类 | 3 区 生化与分子生物学 3 区 医学:研究与实验 3 区 药学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 生化与分子生物学 3 区 医学:研究与实验 3 区 药学
JCR分区:
出版当年[2020]版:
Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Q1 PHARMACOLOGY & PHARMACY Q1 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Q2 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hubei Key Lab Genet & Mol Mech Cardiol Disorders, Wuhan 430074, Peoples R China [2]Huazhong Univ Sci & Technol, Div Cardiol, Wuhan 430074, Peoples R China
通讯作者:
通讯机构: [1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hubei Key Lab Genet & Mol Mech Cardiol Disorders, Wuhan 430074, Peoples R China [2]Huazhong Univ Sci & Technol, Div Cardiol, Wuhan 430074, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:589 今日访问量:0 总访问量:441 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)